文章摘要
符荣朋,宁小英,吴 苑,李景濠,熊文生.基于TLR4/MyD88/NF-κB信号通路探讨安肠汤联合艾灸治疗肝郁脾虚证腹泻型肠易激综合征的疗效及其机制[J].,2024,(3):470-474
基于TLR4/MyD88/NF-κB信号通路探讨安肠汤联合艾灸治疗肝郁脾虚证腹泻型肠易激综合征的疗效及其机制
Based on TLR4/MyD88/NF-κB Signaling Pathway to Explore Efficacy and Mechanism of Anchang Decoction Combined with Moxibustion in the Treatment of Diarrhea-Predominant Irritable Bowel Syndrome with Liver Stagnation and Spleen Deficiency Syndrome
投稿时间:2023-08-04  修订日期:2023-08-31
DOI:10.13241/j.cnki.pmb.2024.03.013
中文关键词: TLR4/MyD88/NF-κB信号通路  安肠汤  艾灸  腹泻型肠易激综合征  肝郁脾虚证  疗效
英文关键词: TLR4/MyD88/NF-κB signaling pathway  Anchang decoction  Moxibustion  Diarrhea-predominant irritable bowel syndrome  Liver stagnation and spleen deficiency syndrome  Efficacy
基金项目:广东省自然科学基金项目(2017A030310486)
作者单位E-mail
符荣朋 广州中医药大学第一临床医学院 广东 广州 510006 frp_20198109072@163.com 
宁小英 广州中医药大学第一临床医学院 广东 广州 510006  
吴 苑 广州中医药大学第一临床医学院 广东 广州 510006  
李景濠 佛山市南海区人民医院中医科 广东 佛山 528200  
熊文生 广州中医药大学第一附属医院脾胃病科 广东 广州 510405  
摘要点击次数: 109
全文下载次数: 92
中文摘要:
      摘要 目的:基于Toll样受体4(TLR4)/髓样分化因子88(MyD88)/核因子-κB(NF-κB)信号通路探讨安肠汤联合艾灸治疗肝郁脾虚证腹泻型肠易激综合征(IBS)的疗效及其机制。方法:采用随机数字表法,将广州中医药大学第一附属医院在2019年4月~2022年12月期间收治的108例腹泻型IBS患者分为对照组(常规药物联合艾灸治疗,n=54)和研究组(对照组基础上接受安肠汤治疗,n=54)。对比两组疗效、中医证候总积分、IBS症状严重程度问卷(IBS-SSS)评分、肠屏障功能指标、TLR4/MyD88/NF-κB信号通路相关信使核糖核酸(mRNA)表达水平。结果:研究组的临床总有效率高于对照组(P<0.05)。两组治疗后中医证候总积分、IBS-SSS评分下降,且研究组低于对照组(P<0.05)。两组治疗后肠脂肪酸结合蛋白(IFABP)、D-乳酸及二胺氧化酶(DAO)下降,且研究组低于对照组(P<0.05)。两组治疗后TLR4、MyD88、NF-κB mRNA表达下降,且研究组低于对照组(P<0.05)。结论:安肠汤联合艾灸治疗肝郁脾虚证腹泻型IBS患者,可有效改善临床症状和肠屏障功能,疗效较好,可能与调节TLR4/MyD88/NF-κB信号通路有关。
英文摘要:
      ABSTRACT Objective: Based on Toll-like receptor 4 (TLR4)/myeloid differentiation factor 88 (MyD88)/nuclear factor-κB (NF-κB) signaling pathway to explore efficacy and mechanism of anchang decoction combined with moxibustion in the treatment of diarrhea-predominant irritable bowel syndrome (IBS) with liver stagnation and spleen deficiency syndrome. Methods: According to random number table method, 108 patients with diarrhea type IBS who were admitted to the First Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine from April 2019 to December 2022 were divided into control group (treated with conventional drugs combined with moxibustion, n=54) and study group (treated with Anchang Tang on the basis of the control group, n=54). The efficacy, chinese medicine syndrome total scores, IBS symptom severity questionnaire(IBS-SSS) score, intestinal barrier function index, TLR4/MyD88/NF-κB signaling pathway related messenger ribonucleic acid (mRNA) expression level were compared between two groups. Results: The total clinical effective rate in study group was higher than that in control group (P<0.05). Chinese medicine syndrome total scores and IBS-SSS scores in two groups decreased after treatment, and study group was lower than that of control group (P<0.05). The intestinal fatty acid binding protein (IFABP), D-lactate and diamine oxidase (DAO) decreased in two groups after treatment, and study group was lower than that of control group (P<0.05). TLR4, MyD88 and NF-κB mRNA decreased expression in two groups after treatment, and study group was lower than that of control group (P<0.05). Conclusion: Anchang decoction combine with moxibustion can effectively improve the clinical symptoms and intestinal barrier function of diarrhea-predominant IBS patients with liver depression and spleen deficiency syndrome, and the curative effect is good, which may be relate to the regulation of TLR4/MyD88/NF-κB signaling pathway.
查看全文   查看/发表评论  下载PDF阅读器
关闭